Comparative Study between Chromitron Versus Metformin as an Adjuvant Agent for Ovulation Induction with Letrozole in Patients with Polycystic Ovary Syndrome

Abstract

Background: Polycystic ovary syndrome (PCOS) is a prevalent reproductive endocrine condition affecting many young women globally.  Metformin being the primary treatment for type two diabetes may affect ovulation.

Objective: To evaluate the impacts of  supplementation of chromium picolinate with induction of ovulation in PCOS on those of metformin supplementation, focusing on the  effects on the response of the ovary, sensitivity of insulin, & rate of pregnancy.

Materials & Methods: This was a double-blinded and  prospective research that was carried out on 120 women who were undergoing ovulation induction and were separated into two groups,  each consisting of 60 infertile women who met the Rotterdam criteria for PCOS in 2017. The study was conducted at Damanhour Medical  National Institute from August 2023 to January 2024.

Results: There wasn’t significant variance among the two groups in terms of  demographic characteristics, cumulative pregnancy, & ovulation rate. We started the pretreatment at month-1, made a change from  month-1 to month-3, and continued the change from month1. Fasting insulin during the follow-up was considerably lower in comparison  with the baseline level in each group. Compared to the chromium group, the metformin group was noticeably lower.

Conclusion: We  advise some PCOS patients to switch from metformin to chromium picolinate because it was less likely to cause side effects, was better  tolerated, and did not significantly differ from the other group regarding rates of pregnancy and ovulation.